Results 161 to 170 of about 57,926 (263)

A Novel Patient‐Specific Landmark‐Guided Approach for Intramuscular Botulinum Neurotoxin Injections Into the Rotator Cuff: A Cadaveric Study

open access: yesClinical Anatomy, EarlyView.
ABSTRACT Myofascial pain syndrome (MFPS) causes chronic shoulder pain. Supraspinatus and infraspinatus, rotator cuff muscles innervated by the suprascapular nerve, are commonly affected. Intramuscular botulinum neurotoxin (BoNT) injections near motor points (i.e., visible nerve branch entry sites used as a proxy for motor endplates) are an effective ...
Dave Osinachukwu Duru   +5 more
wiley   +1 more source

Free Phenolic Hydroxyl Groups Govern the Anticancer Activity of α‐Mangostin: A Structure–Activity Relationship Insight

open access: yesChemFoodChem, EarlyView.
Free phenolic hydroxyl groups in the chemical structure of the natural xanthone α‐mangostin (MGT) contribute positively to achieving the anticancer profile against murine colon cancer, murine triple negative breast cancer, and human osteosarcoma cancer. ABSTRACT The α‐mangostin (MGT) is a natural xanthone obtained from the pericarp of mangosteen fruit (
Otávio Augusto Chaves   +7 more
wiley   +1 more source

Extracellularly Activatable Conjugates of RGD Peptidomimetics and Cryptophycin for αVβ3‐Targeted Cancer Therapy

open access: yesChemistry – A European Journal, EarlyView.
Integrin αVβ3‐targeting small‐molecule drug conjugates (SMDCs) were synthesized by conjugating a cryptophycin payload through a neutrophil elastase‐cleavable NPV‐PABC linker. RGD peptidomimetic and linker epimers served as controls for targeting and enzymatic cleavage, and the resulting conjugates displayed subnanomolar cytotoxicity in vitro.
Dominic Seißenschmidt   +3 more
wiley   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy